Ovid Therapeutics Inc. (OVID) is a pre-commercial stage CNS drug developer with no marketed products. Under a liquidation lens as of December 31, 2025, the recovery posture is marginally positive at face value but thin and dependent almost entirely on liquid financial assets. Total assets of $150.9M are dominated by cash/equivalents ($13.2M), marketable securities ($77.3M fair value, split $56.5M current and $20.8M noncurrent), restricted cash ($1.9M), a long-term equity investment in Graviton preferred stock ($42.0M, no readily determinable fair value), and an ROU asset ($11.6M, zero liquidation value). PP&E net book value is $0.25M (fully depreciated furniture and leasehold improvements); applying a 50-70% haircut yields roughly $0.1-0.2M. Intangibles are zero. The Graviton investment ($42.0M carrying value) is Level 3 illiquid preferred stock in a private company — under liquidation, this warrants a severe haircut (50%+ or more); the filing discloses the associated OV888 program is paused pending regulatory feedback. The filing discusses $21.1M of unrealized gains on equity investments in 2025, the bulk attributable to the Graviton holding based on observable price changes, but no readily determinable fair value market exists. Total liabilities are $20.3M, comprising current liabilities of $8.3M (AP $2.0M, accrued expenses $4.9M, current lease liability $1.4M) and noncurrent liabilities of approximately $12.0M (long-term operating lease liability). The lease represents the most significant fixed obligation: undiscounted future payments total $17.0M through 2033, with a present-value liability of $13.4M. In liquidation, the lease does not extinguish at face value; the full $17.0M undiscounted commitment (or at minimum the PV liability of $13.4M) remains a claim. Netting liquid assets at 100% (cash/equivalents ~$13.2M + marketable securities ~$77.3M + restricted cash ~$1.9M = ~$92.4M) against total face-value liabilities of $20.3M yields approximately $72M before haircut on the illiquid Graviton stake and the lease surplus. However, the Graviton stake is the key uncertainty: a distressed realization could reduce that $42M carrying value materially. MFFAIS CLV/LLV/OLV are all reported at -$7.1M, suggesting a more conservative stance on the illiquid equity investment and/or the lease net present value offset. The 2025 Private Placement raised $75.1M net in October 2025 (57,722 shares of Series B Preferred Stock, all mandatorily converted to 57.7M common shares by December 2025), substantially improving the liquid asset base versus the prior year total of $53.1M. Subsequent to period end, a $60M follow-on offering was announced (March 2026), further increasing the cash runway but not reflected in the balance sheet. No debt instruments, no pension, no inventory. The royalty monetization liability (formerly $30M recognized as a FV gain in 2024 when settled/extinguished) is no longer on the balance sheet, removing a previously material liability.
▼ Community Notes